nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyl aminolevulinate—FCGR1A—Interferon gamma signaling—HLA-C—ankylosing spondylitis	0.0397	0.0834	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Antigen processing-Cross presentation—HLA-C—ankylosing spondylitis	0.0353	0.0741	CbGpPWpGaD
Methyl aminolevulinate—Vitreous detachment—Dexamethasone—ankylosing spondylitis	0.0307	0.0586	CcSEcCtD
Methyl aminolevulinate—Vitreous detachment—Betamethasone—ankylosing spondylitis	0.0307	0.0586	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—ERAP1—ankylosing spondylitis	0.0245	0.0515	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IL1R2—ankylosing spondylitis	0.0238	0.05	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon gamma signaling—HLA-B—ankylosing spondylitis	0.0235	0.0493	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon gamma signaling—HLA-A—ankylosing spondylitis	0.0217	0.0457	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.0211	0.0444	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Antigen processing-Cross presentation—HLA-B—ankylosing spondylitis	0.0208	0.0438	CbGpPWpGaD
Methyl aminolevulinate—Localized exfoliation—Triamcinolone—ankylosing spondylitis	0.0206	0.0394	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—HLA-C—ankylosing spondylitis	0.0194	0.0407	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Antigen processing-Cross presentation—HLA-A—ankylosing spondylitis	0.0193	0.0406	CbGpPWpGaD
Methyl aminolevulinate—Allergic contact dermatitis—Triamcinolone—ankylosing spondylitis	0.0159	0.0304	CcSEcCtD
Methyl aminolevulinate—Allergic contact dermatitis—Dexamethasone—ankylosing spondylitis	0.0144	0.0275	CcSEcCtD
Methyl aminolevulinate—Allergic contact dermatitis—Betamethasone—ankylosing spondylitis	0.0144	0.0275	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—HLA-C—ankylosing spondylitis	0.0141	0.0296	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—HLA-C—ankylosing spondylitis	0.0129	0.0272	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—KIR3DL1—ankylosing spondylitis	0.0128	0.0269	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.0121	0.0255	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CARD9—ankylosing spondylitis	0.0116	0.0243	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—HLA-B—ankylosing spondylitis	0.0115	0.0241	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	0.0112	0.0236	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—HLA-A—ankylosing spondylitis	0.0106	0.0223	CbGpPWpGaD
Methyl aminolevulinate—Skin hyperpigmentation—Triamcinolone—ankylosing spondylitis	0.00935	0.0178	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Methylprednisolone—ankylosing spondylitis	0.00933	0.0178	CcSEcCtD
Methyl aminolevulinate—Keratitis—Prednisolone—ankylosing spondylitis	0.00932	0.0178	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Dexamethasone—ankylosing spondylitis	0.00848	0.0162	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Betamethasone—ankylosing spondylitis	0.00848	0.0162	CcSEcCtD
Methyl aminolevulinate—Blister—Prednisolone—ankylosing spondylitis	0.00839	0.016	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—HLA-B—ankylosing spondylitis	0.00833	0.0175	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.00809	0.017	CbGpPWpGaD
Methyl aminolevulinate—Keratitis—Betamethasone—ankylosing spondylitis	0.00778	0.0148	CcSEcCtD
Methyl aminolevulinate—Keratitis—Dexamethasone—ankylosing spondylitis	0.00778	0.0148	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—IL1R2—ankylosing spondylitis	0.00776	0.0163	CbGpPWpGaD
Methyl aminolevulinate—Blister—Triamcinolone—ankylosing spondylitis	0.00771	0.0147	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—HLA-A—ankylosing spondylitis	0.00771	0.0162	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.00765	0.0161	CbGpPWpGaD
Methyl aminolevulinate—Stinging—Prednisolone—ankylosing spondylitis	0.00746	0.0142	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—ERAP1—ankylosing spondylitis	0.00736	0.0155	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—HLA-C—ankylosing spondylitis	0.00726	0.0153	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.00709	0.0149	CbGpPWpGaD
Methyl aminolevulinate—Eye irritation—Prednisolone—ankylosing spondylitis	0.00708	0.0135	CcSEcCtD
Methyl aminolevulinate—Blister—Dexamethasone—ankylosing spondylitis	0.007	0.0134	CcSEcCtD
Methyl aminolevulinate—Blister—Betamethasone—ankylosing spondylitis	0.007	0.0134	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.00697	0.0146	CbGpPWpGaD
Methyl aminolevulinate—Stinging—Triamcinolone—ankylosing spondylitis	0.00686	0.0131	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—CARD9—ankylosing spondylitis	0.00673	0.0141	CbGpPWpGaD
Methyl aminolevulinate—Stinging—Dexamethasone—ankylosing spondylitis	0.00623	0.0119	CcSEcCtD
Methyl aminolevulinate—Stinging—Betamethasone—ankylosing spondylitis	0.00623	0.0119	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Methotrexate—ankylosing spondylitis	0.00617	0.0118	CcSEcCtD
Methyl aminolevulinate—Ulcer—Triamcinolone—ankylosing spondylitis	0.00588	0.0112	CcSEcCtD
Methyl aminolevulinate—Dermatitis contact—Triamcinolone—ankylosing spondylitis	0.0055	0.0105	CcSEcCtD
Methyl aminolevulinate—Ulcer—Dexamethasone—ankylosing spondylitis	0.00533	0.0102	CcSEcCtD
Methyl aminolevulinate—Ulcer—Betamethasone—ankylosing spondylitis	0.00533	0.0102	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CD79A—ankylosing spondylitis	0.00531	0.0112	CbGpPWpGaD
Methyl aminolevulinate—Skin exfoliation—Triamcinolone—ankylosing spondylitis	0.00531	0.0101	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Methylprednisolone—ankylosing spondylitis	0.0053	0.0101	CcSEcCtD
Methyl aminolevulinate—Burning sensation—Methotrexate—ankylosing spondylitis	0.00529	0.0101	CcSEcCtD
Methyl aminolevulinate—Dermatitis contact—Dexamethasone—ankylosing spondylitis	0.00499	0.00951	CcSEcCtD
Methyl aminolevulinate—Dermatitis contact—Betamethasone—ankylosing spondylitis	0.00499	0.00951	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Betamethasone—ankylosing spondylitis	0.00482	0.00919	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Dexamethasone—ankylosing spondylitis	0.00482	0.00919	CcSEcCtD
Methyl aminolevulinate—Skin ulcer—Methotrexate—ankylosing spondylitis	0.00472	0.009	CcSEcCtD
Methyl aminolevulinate—Ulcer—Prednisone—ankylosing spondylitis	0.00465	0.00886	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Prednisolone—ankylosing spondylitis	0.00459	0.00876	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.00433	0.00911	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—HLA-B—ankylosing spondylitis	0.00429	0.00902	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—HLA-C—ankylosing spondylitis	0.00423	0.00888	CbGpPWpGaD
Methyl aminolevulinate—Dermatitis bullous—Triamcinolone—ankylosing spondylitis	0.00422	0.00806	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Prednisone—ankylosing spondylitis	0.0042	0.008	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.00412	0.00866	CbGpPWpGaD
Methyl aminolevulinate—Eye pain—Betamethasone—ankylosing spondylitis	0.00406	0.00774	CcSEcCtD
Methyl aminolevulinate—Eye pain—Dexamethasone—ankylosing spondylitis	0.00406	0.00774	CcSEcCtD
Methyl aminolevulinate—Ulcer—Methotrexate—ankylosing spondylitis	0.00388	0.00741	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Betamethasone—ankylosing spondylitis	0.00383	0.00731	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Dexamethasone—ankylosing spondylitis	0.00383	0.00731	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.00382	0.00803	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CRP—ankylosing spondylitis	0.00379	0.00797	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IL1RN—ankylosing spondylitis	0.00367	0.00772	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—TLR4—ankylosing spondylitis	0.00364	0.00764	CbGpPWpGaD
Methyl aminolevulinate—Skin exfoliation—Methotrexate—ankylosing spondylitis	0.00351	0.00669	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—CD79A—ankylosing spondylitis	0.00322	0.00678	CbGpPWpGaD
Methyl aminolevulinate—Face oedema—Prednisone—ankylosing spondylitis	0.00308	0.00587	CcSEcCtD
Methyl aminolevulinate—Erythema—Prednisolone—ankylosing spondylitis	0.00264	0.00504	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—IL1A—ankylosing spondylitis	0.00264	0.00556	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CD40LG—ankylosing spondylitis	0.00263	0.00552	CbGpPWpGaD
Methyl aminolevulinate—Eye disorder—Methylprednisolone—ankylosing spondylitis	0.0026	0.00497	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—HLA-B—ankylosing spondylitis	0.0025	0.00525	CbGpPWpGaD
Methyl aminolevulinate—Erythema—Triamcinolone—ankylosing spondylitis	0.00243	0.00464	CcSEcCtD
Methyl aminolevulinate—Erythema—Methylprednisolone—ankylosing spondylitis	0.00243	0.00463	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Betamethasone—ankylosing spondylitis	0.00237	0.00452	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Dexamethasone—ankylosing spondylitis	0.00237	0.00452	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—HLA-A—ankylosing spondylitis	0.00232	0.00487	CbGpPWpGaD
Methyl aminolevulinate—Discomfort—Prednisolone—ankylosing spondylitis	0.00222	0.00424	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—CRP—ankylosing spondylitis	0.00221	0.00464	CbGpPWpGaD
Methyl aminolevulinate—Erythema—Betamethasone—ankylosing spondylitis	0.00221	0.00421	CcSEcCtD
Methyl aminolevulinate—Erythema—Dexamethasone—ankylosing spondylitis	0.00221	0.00421	CcSEcCtD
Methyl aminolevulinate—Oedema—Prednisolone—ankylosing spondylitis	0.00216	0.00412	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—TLR4—ankylosing spondylitis	0.00212	0.00445	CbGpPWpGaD
Methyl aminolevulinate—Photosensitivity reaction—Methotrexate—ankylosing spondylitis	0.0021	0.00401	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Prednisone—ankylosing spondylitis	0.00206	0.00393	CcSEcCtD
Methyl aminolevulinate—Discomfort—Triamcinolone—ankylosing spondylitis	0.00204	0.0039	CcSEcCtD
Methyl aminolevulinate—Discomfort—Methylprednisolone—ankylosing spondylitis	0.00204	0.00389	CcSEcCtD
Methyl aminolevulinate—Oedema—Triamcinolone—ankylosing spondylitis	0.00198	0.00378	CcSEcCtD
Methyl aminolevulinate—Infection—Triamcinolone—ankylosing spondylitis	0.00197	0.00376	CcSEcCtD
Methyl aminolevulinate—Infection—Methylprednisolone—ankylosing spondylitis	0.00197	0.00375	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Prednisolone—ankylosing spondylitis	0.00194	0.0037	CcSEcCtD
Methyl aminolevulinate—Erythema—Prednisone—ankylosing spondylitis	0.00192	0.00366	CcSEcCtD
Methyl aminolevulinate—Discomfort—Dexamethasone—ankylosing spondylitis	0.00186	0.00354	CcSEcCtD
Methyl aminolevulinate—Discomfort—Betamethasone—ankylosing spondylitis	0.00186	0.00354	CcSEcCtD
Methyl aminolevulinate—Pain—Prednisolone—ankylosing spondylitis	0.00184	0.00352	CcSEcCtD
Methyl aminolevulinate—Oedema—Dexamethasone—ankylosing spondylitis	0.0018	0.00343	CcSEcCtD
Methyl aminolevulinate—Oedema—Betamethasone—ankylosing spondylitis	0.0018	0.00343	CcSEcCtD
Methyl aminolevulinate—Infection—Dexamethasone—ankylosing spondylitis	0.00179	0.00341	CcSEcCtD
Methyl aminolevulinate—Infection—Betamethasone—ankylosing spondylitis	0.00179	0.00341	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Triamcinolone—ankylosing spondylitis	0.00178	0.0034	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Methylprednisolone—ankylosing spondylitis	0.00178	0.00339	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Methotrexate—ankylosing spondylitis	0.00172	0.00329	CcSEcCtD
Methyl aminolevulinate—Urticaria—Prednisolone—ankylosing spondylitis	0.00171	0.00327	CcSEcCtD
Methyl aminolevulinate—Fatigue—Triamcinolone—ankylosing spondylitis	0.00171	0.00326	CcSEcCtD
Methyl aminolevulinate—Fatigue—Methylprednisolone—ankylosing spondylitis	0.00171	0.00326	CcSEcCtD
Methyl aminolevulinate—Pain—Triamcinolone—ankylosing spondylitis	0.0017	0.00324	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Dexamethasone—ankylosing spondylitis	0.00162	0.00308	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Betamethasone—ankylosing spondylitis	0.00162	0.00308	CcSEcCtD
Methyl aminolevulinate—Discomfort—Prednisone—ankylosing spondylitis	0.00162	0.00308	CcSEcCtD
Methyl aminolevulinate—Erythema—Methotrexate—ankylosing spondylitis	0.00161	0.00306	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.00159	0.00303	CcSEcCtD
Methyl aminolevulinate—Urticaria—Triamcinolone—ankylosing spondylitis	0.00158	0.00301	CcSEcCtD
Methyl aminolevulinate—Urticaria—Methylprednisolone—ankylosing spondylitis	0.00157	0.003	CcSEcCtD
Methyl aminolevulinate—Oedema—Prednisone—ankylosing spondylitis	0.00157	0.00299	CcSEcCtD
Methyl aminolevulinate—Infection—Prednisone—ankylosing spondylitis	0.00156	0.00297	CcSEcCtD
Methyl aminolevulinate—Fatigue—Betamethasone—ankylosing spondylitis	0.00155	0.00296	CcSEcCtD
Methyl aminolevulinate—Fatigue—Dexamethasone—ankylosing spondylitis	0.00155	0.00296	CcSEcCtD
Methyl aminolevulinate—Pain—Betamethasone—ankylosing spondylitis	0.00154	0.00294	CcSEcCtD
Methyl aminolevulinate—Pain—Dexamethasone—ankylosing spondylitis	0.00154	0.00294	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.00146	0.00279	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.00146	0.00278	CcSEcCtD
Methyl aminolevulinate—Urticaria—Dexamethasone—ankylosing spondylitis	0.00143	0.00273	CcSEcCtD
Methyl aminolevulinate—Urticaria—Betamethasone—ankylosing spondylitis	0.00143	0.00273	CcSEcCtD
Methyl aminolevulinate—Dizziness—Prednisolone—ankylosing spondylitis	0.00143	0.00272	CcSEcCtD
Methyl aminolevulinate—Asthenia—Triamcinolone—ankylosing spondylitis	0.00142	0.00272	CcSEcCtD
Methyl aminolevulinate—Asthenia—Methylprednisolone—ankylosing spondylitis	0.00142	0.00271	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Prednisone—ankylosing spondylitis	0.00141	0.00269	CcSEcCtD
Methyl aminolevulinate—Pruritus—Triamcinolone—ankylosing spondylitis	0.0014	0.00268	CcSEcCtD
Methyl aminolevulinate—Pruritus—Methylprednisolone—ankylosing spondylitis	0.0014	0.00267	CcSEcCtD
Methyl aminolevulinate—Rash—Prednisolone—ankylosing spondylitis	0.00136	0.00259	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Prednisolone—ankylosing spondylitis	0.00136	0.00259	CcSEcCtD
Methyl aminolevulinate—Fatigue—Prednisone—ankylosing spondylitis	0.00135	0.00258	CcSEcCtD
Methyl aminolevulinate—Headache—Prednisolone—ankylosing spondylitis	0.00135	0.00258	CcSEcCtD
Methyl aminolevulinate—Discomfort—Methotrexate—ankylosing spondylitis	0.00135	0.00258	CcSEcCtD
Methyl aminolevulinate—Dizziness—Triamcinolone—ankylosing spondylitis	0.00131	0.0025	CcSEcCtD
Methyl aminolevulinate—Dizziness—Methylprednisolone—ankylosing spondylitis	0.00131	0.0025	CcSEcCtD
Methyl aminolevulinate—Infection—Methotrexate—ankylosing spondylitis	0.0013	0.00248	CcSEcCtD
Methyl aminolevulinate—Asthenia—Dexamethasone—ankylosing spondylitis	0.00129	0.00246	CcSEcCtD
Methyl aminolevulinate—Asthenia—Betamethasone—ankylosing spondylitis	0.00129	0.00246	CcSEcCtD
Methyl aminolevulinate—Nausea—Prednisolone—ankylosing spondylitis	0.00128	0.00244	CcSEcCtD
Methyl aminolevulinate—Pruritus—Dexamethasone—ankylosing spondylitis	0.00127	0.00243	CcSEcCtD
Methyl aminolevulinate—Pruritus—Betamethasone—ankylosing spondylitis	0.00127	0.00243	CcSEcCtD
Methyl aminolevulinate—Rash—Triamcinolone—ankylosing spondylitis	0.00125	0.00239	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Triamcinolone—ankylosing spondylitis	0.00125	0.00238	CcSEcCtD
Methyl aminolevulinate—Rash—Methylprednisolone—ankylosing spondylitis	0.00125	0.00238	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.00125	0.00238	CcSEcCtD
Methyl aminolevulinate—Urticaria—Prednisone—ankylosing spondylitis	0.00125	0.00238	CcSEcCtD
Methyl aminolevulinate—Headache—Triamcinolone—ankylosing spondylitis	0.00124	0.00237	CcSEcCtD
Methyl aminolevulinate—Headache—Methylprednisolone—ankylosing spondylitis	0.00124	0.00237	CcSEcCtD
Methyl aminolevulinate—Dizziness—Dexamethasone—ankylosing spondylitis	0.00119	0.00227	CcSEcCtD
Methyl aminolevulinate—Dizziness—Betamethasone—ankylosing spondylitis	0.00119	0.00227	CcSEcCtD
Methyl aminolevulinate—Nausea—Triamcinolone—ankylosing spondylitis	0.00118	0.00225	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Methotrexate—ankylosing spondylitis	0.00118	0.00224	CcSEcCtD
Methyl aminolevulinate—Nausea—Methylprednisolone—ankylosing spondylitis	0.00118	0.00224	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Prednisone—ankylosing spondylitis	0.00115	0.0022	CcSEcCtD
Methyl aminolevulinate—Rash—Betamethasone—ankylosing spondylitis	0.00114	0.00217	CcSEcCtD
Methyl aminolevulinate—Rash—Dexamethasone—ankylosing spondylitis	0.00114	0.00217	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Dexamethasone—ankylosing spondylitis	0.00113	0.00216	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Betamethasone—ankylosing spondylitis	0.00113	0.00216	CcSEcCtD
Methyl aminolevulinate—Fatigue—Methotrexate—ankylosing spondylitis	0.00113	0.00215	CcSEcCtD
Methyl aminolevulinate—Headache—Dexamethasone—ankylosing spondylitis	0.00113	0.00215	CcSEcCtD
Methyl aminolevulinate—Headache—Betamethasone—ankylosing spondylitis	0.00113	0.00215	CcSEcCtD
Methyl aminolevulinate—Asthenia—Prednisone—ankylosing spondylitis	0.00112	0.00215	CcSEcCtD
Methyl aminolevulinate—Pain—Methotrexate—ankylosing spondylitis	0.00112	0.00214	CcSEcCtD
Methyl aminolevulinate—Pruritus—Prednisone—ankylosing spondylitis	0.00111	0.00212	CcSEcCtD
Methyl aminolevulinate—Nausea—Dexamethasone—ankylosing spondylitis	0.00107	0.00204	CcSEcCtD
Methyl aminolevulinate—Nausea—Betamethasone—ankylosing spondylitis	0.00107	0.00204	CcSEcCtD
Methyl aminolevulinate—Urticaria—Methotrexate—ankylosing spondylitis	0.00104	0.00199	CcSEcCtD
Methyl aminolevulinate—Dizziness—Prednisone—ankylosing spondylitis	0.00104	0.00198	CcSEcCtD
Methyl aminolevulinate—Rash—Prednisone—ankylosing spondylitis	0.000988	0.00189	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Prednisone—ankylosing spondylitis	0.000988	0.00188	CcSEcCtD
Methyl aminolevulinate—Headache—Prednisone—ankylosing spondylitis	0.000982	0.00187	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.000965	0.00184	CcSEcCtD
Methyl aminolevulinate—Asthenia—Methotrexate—ankylosing spondylitis	0.00094	0.00179	CcSEcCtD
Methyl aminolevulinate—Nausea—Prednisone—ankylosing spondylitis	0.000931	0.00178	CcSEcCtD
Methyl aminolevulinate—Pruritus—Methotrexate—ankylosing spondylitis	0.000927	0.00177	CcSEcCtD
Methyl aminolevulinate—Dizziness—Methotrexate—ankylosing spondylitis	0.000866	0.00165	CcSEcCtD
Methyl aminolevulinate—Rash—Methotrexate—ankylosing spondylitis	0.000826	0.00158	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Methotrexate—ankylosing spondylitis	0.000825	0.00157	CcSEcCtD
Methyl aminolevulinate—Headache—Methotrexate—ankylosing spondylitis	0.000821	0.00157	CcSEcCtD
Methyl aminolevulinate—Nausea—Methotrexate—ankylosing spondylitis	0.000778	0.00148	CcSEcCtD
